Centessa Pharmaceuticals (NASDAQ:CNTA) Insider Sells $300,000.00 in Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $30.00, for a total transaction of $300,000.00. Following the transaction, the insider directly owned 188,801 shares in the company, valued at approximately $5,664,030. The trade was a 5.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Mario Alberto Accardi also recently made the following trade(s):

• On Monday, October 27th, Mario Alberto Accardi sold 8,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $25.00, for a total transaction of $200,000.00.
• On Tuesday, September 16th, Mario Alberto Accardi sold 8,172 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $21.40, for a total transaction of $174,880.80.
• On Tuesday, September 9th, Mario Alberto Accardi sold 7,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $20.00, for a total transaction of $140,000.00.

Centessa Pharmaceuticals Stock Down 1.4%

Shares of NASDAQ CNTA traded down $0.41 during midday trading on Monday, reaching $29.50. 828,533 shares of the company’s stock were exchanged, compared to its average volume of 1,142,784. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $9.60 and a 52-week high of $30.58. The business’s fifty day moving average price is $25.09 and its two-hundred day moving average price is $19.24. The stock has a market capitalization of $3.97 billion, a PE ratio of -16.12 and a beta of 1.55.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CNTA shares. Truist Financial set a $30.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, November 5th. Guggenheim upped their target price on shares of Centessa Pharmaceuticals from $28.00 to $43.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Wells Fargo & Company lifted their price target on Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. Lifesci Capital upgraded Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Finally, Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, October 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and an average price target of $35.50.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Large investors have recently bought and sold shares of the business. Russell Investments Group Ltd. bought a new position in shares of Centessa Pharmaceuticals during the first quarter valued at approximately $3,273,000. Caitong International Asset Management Co. Ltd boosted its position in Centessa Pharmaceuticals by 15,209.5% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after purchasing an additional 3,194 shares during the period. Regents of The University of California bought a new position in Centessa Pharmaceuticals during the 1st quarter worth $1,177,000. Lord Abbett & CO. LLC increased its position in Centessa Pharmaceuticals by 1.3% in the first quarter. Lord Abbett & CO. LLC now owns 446,196 shares of the company’s stock worth $6,416,000 after buying an additional 5,701 shares during the period. Finally, Fox Run Management L.L.C. acquired a new stake in Centessa Pharmaceuticals in the first quarter worth $160,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.